Faron Pharmaceuticals hails the continued success of lead drug in...
Faron Pharmaceuticals Limited (AIM:FARN) has announced initial positive results from phase II of its BEXMAB trial of its cancer treatment Bexmarilimab, indicating significant progress in treating myelodysplastic syndrome (MDS) patients who have previously …